Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

(2011) M. A. Fanale et al.   CLINICAL CANCER RESEARCH

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

(2011) Kelley V. Foyil et al.   LEUKEMIA & LYMPHOMA

Crizotinib in Anaplastic Large-Cell Lymphoma

(2011) Carlo Gambacorti-Passerini et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

(2010) N. Schmitz et al.   BLOOD

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial

(2010) Marie-Cécile Le Deley et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

(2009) Andres Forero-Torres et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma

(2009) R. R. Singh et al.   CANCER RESEARCH

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

(2008) S. Mercadal et al.   ANNALS OF ONCOLOGY

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

(2008) Ezogelin Oflazoglu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire

(2008) Steven Le Gouill et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

(2008) Peter Reimer et al.   JOURNAL OF CLINICAL ONCOLOGY